Complete an online health assessment
Skip the doctor’s office and answer a short, confidential health questionnaire.

Rybelsus®Prescription medication (semaglutide)
Through Phoenix, you can get Rybelsus® prescribed by a licensed healthcare provider who reviews your health history and decides whether a prescription is appropriate. If prescribed, medication is dispensed by a licensed Canadian pharmacy, with discreet and free delivery to your door for eligible orders.
1.5 mg, 4 mg, 9 mg
Online health assessment: $0.
Follow-up consultations cost $40–$50 each.
For new patients, the first follow-up consultation fee is waived with their initial order.
Medication costs are separate.
Free, about 3 minutes.
Assessment
A licensed healthcare provider reviews your responses.
Approval
If appropriate, your prescription is issued.
Delivery
Your medication is shipped directly to your door at no additional delivery cost.
Ongoing support
Stay connected with your provider through regular monthly check-ins.

Medically reviewed by Dr. Mark Broussenko, MD, Medical Director. Reviewed September 2026. Page updated October 2026.
Skip the doctor’s office and answer a short, confidential health questionnaire.

A licensed Canadian practitioner will recommend a treatment plan.

Your treatment is shipped for free, directly to you in discreet packaging.

Your healthcare provider will follow up as part of your monthly consult.





Medication Guide
Find practical information on Rybelsus in Canada, including product facts, prescription access, safety considerations, and questions to discuss with your healthcare provider.

Rybelsus® is a brand of semaglutide tablets made by Novo Nordisk and is available by prescription only in Canada. Its authorized uses are described in the Canadian product monograph. A licensed healthcare provider determines whether it is appropriate for you.
Rybelsus® is available as prescription oral tablets in different formulations. Follow your pharmacy label and the current Canadian product monograph for how to take and store the exact tablets dispensed. Tablet strengths and formulations should not be substituted without your prescriber and pharmacist's guidance.
Reported side effects include nausea, vomiting, diarrhea, constipation and abdominal discomfort. The Canadian product monograph also contains important warnings and contraindications. A healthcare provider should assess your medical history, medications and any relevant risks before prescribing.
Seek urgent medical care for severe or persistent abdominal pain, signs of a serious allergic reaction or other concerning symptoms. Do not change your prescribed medication or administration routine without speaking to your healthcare provider.
Rybelsus and Ozempic contain semaglutide but use different formulations: Rybelsus is an oral tablet taken daily, while Ozempic is an injection taken weekly. Their indications, administration and prescribing considerations must be reviewed individually. They are not directly interchangeable.
Compare product facts using the official Canadian monographs for Rybelsus, Ozempic and other prescription medications. A licensed healthcare provider determines appropriate care.
Tell your provider about your full health history, every prescription and non-prescription medication and supplement you take, and any allergies. Also mention if you are pregnant, planning a pregnancy or breastfeeding, and any personal or family history of thyroid cancer, or any past pancreas, gallbladder, kidney or eye problems.
Your provider reviews your health history and medications to assess whether Rybelsus or another option is appropriate. Share any recent health changes before starting treatment.
Same category. Different medications. Here's how they compare.
Swipe to compare →
| Rybelsus® Semaglutide | Ozempic® Semaglutide | Wegovy® Semaglutide | Generic Semaglutide | Mounjaro® Tirzepatide | Zepbound® Tirzepatide | |
|---|---|---|---|---|---|---|
| Manufacturer | Novo Nordisk | Novo Nordisk | Novo Nordisk | Apotex | Eli Lilly | Eli Lilly |
| Form | Oral tablet | Injection | Injection | Injection | Injection | Injection |
| Frequency | Once daily | Once weekly | Once weekly | Once weekly | Once weekly | Once weekly |
| Starting price | From $324.99 | View pricing | View pricing | View pricing | View pricing | View pricing |
| Online assessment | $0 | $0 | $0 | $0 | $0 | $0 |
Available in Ontario, Quebec, British Columbia, Alberta, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, and Prince Edward Island. Medication availability may vary by prescription and province.
Our team of licensed Canadian providers are dedicated to your health, bringing trusted expertise to every step of your journey.







The whole process was straightforward from the online assessment to delivery. Everything was clearly explained, and getting support when I had a question was quick and easy.
Read moreI liked how easy it was to complete everything online without having to rearrange my day. Communication was clear, the experience felt private, and I always knew what the next step was.
Read moreSigning up was much easier than I expected. The instructions were simple to follow, updates were clear throughout the process, and everything arrived discreetly at my door.
Read moreFind answers to common questions about Rybelsus online in Canada, semaglutide, prescription requirements, safety, and how Phoenix's online assessment process works.
Rybelsus® is a brand of semaglutide tablets made by Novo Nordisk. It is prescription-only in Canada. Its authorized uses are listed in the Canadian product monograph in Health Canada's Drug Product Database.
Rybelsus is a tablet taken by mouth once a day, as prescribed. Ozempic and Wegovy are semaglutide injections. The products are not interchangeable.
No. Rybelsus® is available in original and updated tablet formulations in Canada. They have different tablet strengths and must not be substituted milligram for milligram. A healthcare provider or pharmacist can confirm the prescribed formulation and explain the instructions. Do not change formulations without professional guidance; follow your pharmacy label and the current Canadian product monograph.
Yes. Rybelsus is prescription-only in Canada. A licensed prescriber must review your health history and current medications first.
Consult the Canadian Rybelsus® product monograph, including its Patient Medication Information. The monograph describes product-specific administration instructions and warnings; your pharmacist can explain the instructions for the formulation dispensed.
Coverage depends on your private plan or provincial drug program and its criteria. Check with your insurer before you start. Current Phoenix pricing is on the pricing page.
A licensed Canadian healthcare provider authorized to practise in your province reviews your health history and medications. They may request more information, recommend another care option or an in-person visit, and decide whether a prescription is clinically appropriate. A prescription is not guaranteed.
Yes. Phoenix's online health assessment is always free. Follow-up consultations cost between $40 and $50 each. For new patients, the fee for the first follow-up consultation is waived with their initial order. Medication costs are separate if prescribed, and a prescription is not guaranteed.
If a prescription is issued, a licensed Canadian pharmacy dispenses the medication. Phoenix offers discreet delivery to eligible Canadian addresses, with free delivery on qualifying orders. Timing and availability depend on the pharmacy, product and destination.
You can contact the Phoenix care team through your secure account. Renewals are not automatic; updated information and a provider review may be needed before another prescription is issued. Follow-up consultation fees may apply.
Complete a private online health assessment. A licensed Canadian healthcare provider reviews your information and determines whether any prescription is clinically appropriate.

a month, starting price if prescribed
About 3 minutes. Completing an assessment does not guarantee a prescription.